SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) – Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation in women’s health, today announced that it has been selected to present the company at BIO Digital 2021, which will be held virtually June 10-11 and 14-18, 2021.
Sabrina Martucci Johnson, President and CEO of Daré, will provide an overview of the company’s innovative research product portfolio. The presentation will be available on request for registered participants from June 10e at 9 a.m. Eastern Time. Registration information for 2021 BIO Digital can be found here.
At the end of the event, a recording of Ms. Johnson’s presentation will be available under “Presentations, Events and Webcasts” in the Investors section of the Company’s website at http://ir.darebioscience.com until July 2, 2021.
About Daré Biosciences
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes, and facilitate comfort for women, primarily in the areas of contraception, vaginal health , sexual health and fertility.
Daré’s product portfolio includes potential first-class candidates in clinical development: Ovaprene®, a new investigational hormone-free monthly intravaginal contraceptive whose commercial rights in the United States are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a new formulation of sildenafil cream to treat female sexual arousal disorders using the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of 2% clindamycin phosphate to treat bacterial vaginosis via a single application; and DARE-HRT1, a bioidentical intravaginal ring combination of estradiol and progesterone for postmenopausal hormone therapy. To learn more about Daré’s complete product candidate portfolio for women’s health and its mission to provide differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce important information about its finances, product candidates, clinical trials, and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings , press releases, public conference calls and webcasts. Daré will use these channels to disseminate important information about the company and may also use social media to communicate important information about the company, its finances, its product candidates, its clinical trials and other matters. The information that Daré publishes on its investor relations site or via social networks may be considered as material information. Daré encourages investors, the media and others interested in the company to consult the information that Daré publishes in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the Company may use to communicate information will be posted on the Investor Relations page of Daré’s website referenced above.
BIO is the world’s largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other countries. BIO members are involved in the research and development of innovative biotechnology products in the fields of health, agriculture, industry and the environment. BIO also hosts the BIO International Convention, the world’s largest gathering of the biotechnology industry, as well as meetings of leading investors and partners held around the world.
Investors on behalf of Daré Bioscience, Inc .:
Allele Capital Partners
Source: Daré Bioscience, Inc.